Startup crowdsourcing for better clinical trial design

Transparency Life Sciences is looking to change up the clinical trial model by introducing opensourcing to the picture. The idea here is to create “more patient-centric, transparent and dramatically less costly clinical development,” the company said in a statement. The company is using digital telemonitoring and crowdsourcing to conduct a clinical trial of Auven Therapeutics’ Kiacta in patients […]

Transparency Life Sciences is looking to change up the clinical trial model by introducing opensourcing to the picture. The idea here is to create “more patient-centric, transparent and dramatically less costly clinical development,” the company said in a statement.

The company is using digital telemonitoring and crowdsourcing to conduct a clinical trial of Auven Therapeutics’ Kiacta in patients with sarcoidosis, a rare inflammatory disease. TLS is additionally working with Genentech for an inflammatory bowel disease opensourced trial, and has several other projects in the pipeline.

It’s basically crowdsourcing among those in the know to find ways to improve clinical trial design, is replacing patient site visits with telemonitoring and other digital tech, and is operating with full data transparency, the company said in a statement.

“Transparency’s focus on crowdsourced design and home-based data collection promises to make clinical trials for orphan indications far more feasible, by aligning clinical endpoints with clinical practice while minimizing geographical barriers,” Marc Foster, co-founder and COO of Transparency Life Sciences, said in the statement.